HAIKOU,
China, Aug. 19, 2024 /PRNewswire/ -- China
Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or
the "Company"), an NYSE American-listed corporation with a
fully-integrated specialty pharmaceuticals subsidiary based in
China, today announced that
through Hainan Helpson Medical and Biotechnology Co., Ltd.
("Helpson"), our wholly owned subsidiary, it expects to launch its
Dry Eye Disease Therapeutic Device in the first quarter of 2025 in
China.
- It is a medical treatment device for dry eye disease under
patent protection;
- The Company, through Helpson, acquired the technology at the
end of 2022 and has subsequently carried out the corresponding
commercialization, as well as the registration and application
process of the product;
- It has completed production commissioning and third-party
testing by now.
In China, the incidence of dry
eye disease is about 21%-30%, second only to myopia. According to
the National Bureau of Statistics of China, the total population of the country by
the end of 2023 is about 1.4 billion, and the number of dry eye
disease patients in China has
approached 400 million. According to Inkwood Research, the
Chinese dry eye disease market is projected at a CAGR of 6.04%
during the forecast period of 2023-2030, and is expected to reach a
market size of $579.51 million by
2030. This figure is expected to continue growing as people become
increasingly dependent on electronic products and the aging problem
intensifies.
Treatments for dry eye-related indications include two forms of
secretagogues, oral and topical, which are widely recommended for
first-line and second-line treatments. A major factor driving the
segment's growth includes the awareness campaigns regarding dry eye
diseases by vision science and optometry. Our device is embedded
with an ophthalmic oxygen enriched atomization therapeutic
instrument.
Using such technology, our device can spray tiny oxygen-rich
droplets evenly into patient's eyes, thereby increasing the
moisture and oxygen supply of the eye surface and improving the
quality and stability of the tear fluid. This type of physical
therapy avoids the side effects that may be brought about by drugs,
and can also effect more directly on the eyes, improving the
effectiveness and comfort of the treatment.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty
pharmaceutical company that develops, manufactures, and markets a
diversified portfolio of products, focusing on conditions with high
incidence and high mortality rates in China, including cardiovascular, CNS,
infectious, and digestive diseases. The Company's cost-effective
business model is driven by market demand and supported by new
GMP-certified product lines covering the major dosage forms. In
addition, the Company has a broad and expanding nationwide
distribution network across all major cities and provinces in
China. The Company's wholly-owned
subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.,
is located in Haikou City,
Hainan Province. For more
information about China Pharma Holdings, Inc., please visit
www.chinapharmaholdings.com. The Company routinely posts important
information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
View original
content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc--expects-to-launch-its-dry-eye-disease-therapeutic-device-in-the-first-quarter-of-2025-302225097.html
SOURCE China Pharma Holdings, Inc.